8-K
filed May 28, 2026, 6:07 AM ET
ticker NDRA
CIK 0001681682
other material
confidence high
sentiment neutral
materiality 0.70
ENDRA raises $3.8M via private placement; believes it regains Nasdaq compliance
ENDRA Life Sciences Inc.
- Gross proceeds ~$3.8M from sale of 578,387 shares (or prefunded warrants) and 1,156,774 warrants at $6.57 per unit.
- Side letter restricts cash use until strategic alternative closes or payment obligation met; grants board observer right.
- Nasdaq notified company of non-compliance on Apr 20, 2026; after offering, company believes equity exceeds $2.5M minimum.
- Offering expected to close May 28, 2026; placement agent Lucid Capital Markets.
- Proceeds for working capital and general corporate purposes.
Key facts
Extracted from this filing and checked against the source text.
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
ENDRA Life Sciences Inc. issued up to 1,156,774 shares of Common Stock of warrant to an accredited investor for per share exercise price of $6.57.
- Security
- warrant
- Shares
- up to 1,156,774 shares of Common Stock
- Purchaser
- an accredited investor
- Consideration
- per share exercise price of $6.57
Exact text from the filing
warrants (the “Common Warrants”) to purchase an aggregate of up to 1,156,774 shares of Common Stock at a per share exercise price of $6.57. Each share of Common Stock (or Pre-Funded Warrant in lieu thereof) and accompanying Common Warrants were sold at a combined purchase price of $6.57.
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
ENDRA Life Sciences Inc. issued 578,387 shares of common stock to an accredited investor for combined purchase price of $6.57.
- Security
- common stock
- Shares
- 578,387 shares
- Purchaser
- an accredited investor
- Consideration
- combined purchase price of $6.57
Exact text from the filing
aggregate of 578,387 shares (the “Shares”) of common stock of the Company, par value $0.0001 per share (the “Common Stock”), and/or prefunded warrants in lieu thereof (the “Prefunded Warrants”), and warrants (the “Common Warrants”) to purchase an aggregate of up to 1,156,774 shares of Common Stock at a per share exercise price of $6.57. Each share of Common Stock (or Pre-Funded Warrant in lieu thereof) and accompanying Common Warrants were sold at a combined purchase price of $6.57.
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
ENDRA Life Sciences Inc. issued up to an aggregate of 100,000 shares of Common Stock of warrant to the Placement Agent.
- Security
- warrant
- Shares
- up to an aggregate of 100,000 shares of Common Stock
- Purchaser
- the Placement Agent
Exact text from the filing
the Company will issue to the Placement Agent prefunded warrants (the “Placement Agent Prefunded Warrants”) to purchase up to an aggregate of 100,000 shares of Common Stock as compensation.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 1.0
ENDRA Life Sciences Inc. entered into Securities Purchase Agreement with an accredited investor valued at approximately $3.8 million (effective 2026-05-27).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- an accredited investor
- Value
- approximately $3.8 million
- Effective
- 2026-05-27
Exact text from the filing
On May 27, 2026, ENDRA Life Sciences Inc., a Delaware corporation (the “Company”), entered into a securities purchase agreement (the “Securities Purchase Agreement”) with an accredited investor (the “Purchaser”) pursuant to which the Company agreed to sell and issue to the Purchaser in a private placement offering (the “Offering”) an aggregate of 578,387 shares (the “Shares”) of common stock of the Company, par value $0.0001 per share (the “Common Stock”), and/or prefunded warrants in lieu thereof (the “Prefunded Warrants”), and warrants (the “Common Warrants”) to purchase an aggregate of up to 1,156,774 shares of Common Stock at a per share exercise price of $6.57.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
ENDRA Life Sciences Inc. entered into Side Letter Agreement with the Purchaser (effective 2026-05-27).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- the Purchaser
- Effective
- 2026-05-27
Exact text from the filing
Concurrently with the entry into the Securities Purchase Agreement, the Company and the Purchaser entered into a side letter agreement (the “Side Letter Agreement”).
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.